Advaxis, Inc. (NASDAQ:ADXS) Will Be Present At The 3rd Annual Jefferies Immuno-Oncology Summit

502
Advaxis

President and Chief Executive Officer of Advaxis, Inc. (NASDAQ:ADXS) Daniel J. O’Connor, will be present on behalf of the company at the 3rd Annual Jefferies Immuno-Oncology Summit. The helm of the presentation will be the key highlights and Company initiatives in the immuno-oncology space.

The clinical stage biotechnology company develops cancer immunotherapies using the proprietary Lm Technology. The technology applies the bioengineered live attenuated Listeria monocytogenes (Lm), cancer immunotherapy agent and commonly used in preclinical studies. Through its generation of cancer fighting T-cells directed against a cancer antigen, it protects the tumor microenvironment from immunologic attack. It also plays a remarkable role in neutralizing Tregs and myeloid-derived suppressor cells (MDSCs).

The main target for Advaxis’ leadLm Technology is the human papillomavirus (HPV)-associated cancers which is currently undergoing different clinical trial phases in invasive cervical cancer, head and neck cancer and anal cancer.

Apparently, axalimogene filolisbac has already received from the U.S. Food and Drug Administration (FDA) orphan drug designation. Other immunotherapy products under Advaxis include ADXS-PSA for prostrate cancer and ADXS-HER2 in HER2 expressing solid tumors. These are the more aggressive types of diseases, with increased chances of relapse and a high level of terminality. As a result the HER2 plays a critical part in immunotherapy for patients. Among the types of HER2 diseases include Breast Cancer, Gastric Cancer, Esophageal Cancer, Osteosarcoma.

Advaxis, Inc prides itself on using its LM Technology to maximize the performance of the whole immune system. As a result, the Killer T cells that are in the immune system efficiently carry out the task of killing cancer cells. The LM Technology teaches the immune system to validate the tumor as an existing threat, thus lessening the mechanism of the tumor’s defense.

Not only a reputable organization, but the performances of the company will add value to the summit and provide insight into new research and progress made. The platform will also provide Advaxis, Inc. with the opportunity to court new partners for its LM Technology.

An ad to help with our costs